Developing HealthPolitics

White House withdraws FDA nominee Overton

The White House withdrew Heidi Overton's nomination to lead the Food and Drug Administration before a scheduled Senate health committee vote. Doubts among Senate Republicans and questions from supporters of Health Secretary Robert F. Kennedy Jr's MAHA movement had emerged days earlier.

Latest update: White House pulls Heidi Overton nomination to lead FDA

Image from Illustration: White House pulls Heidi Overton nomination to lead FDAIllustration

The story so far

On November 11, the Senate health committee scheduled a vote for November 18 on the nomination of Heidi Overton to serve as Food and Drug Administration commissioner. Committee Chair Bill Cassidy remained undecided, and the nomination faced potential opposition from Republicans on the panel. If it passed, the nomination would go to the full Senate, where Republicans were seeking to confirm nominees before Democrats take power in January.

By November 13, doubts emerged among Senate Republicans about Heidi Overton, President Trump's pick to run the FDA, just days before a key vote on her nomination. The FDA had also quietly scuttled the fast-track drug review initiative known as the Commissioner's National Priority Voucher program. The news arrived as the agency faced scrutiny over other health policy decisions and funding cuts.

On November 18, the White House withdrew Heidi Overton's nomination to lead the Food and Drug Administration amid opposition from Senate Republicans. Overton, the White House Domestic Policy Council deputy director, was set to face a key Senate health committee vote Wednesday, where Republicans hold a one-vote majority. She had faced questions from some Republicans and from supporters of Health Secretary Robert F. Kennedy Jr's MAHA movement.

Latest updates

3 updates · newest first
  1. 18 Nov
    New development

    White House pulls Heidi Overton nomination to lead FDA

    The White House withdrew Heidi Overton's nomination to lead the Food and Drug Administration amid opposition from Senate Republicans. Overton, the White House Domestic Policy Council deputy director, was set to face a key Senate health committee vote Wednesday, where Republicans hold a one-vote majority. She had faced questions from some Republicans and from supporters of Health Secretary Robert F. Kennedy Jr's MAHA movement.

    The Hill ↗STAT ↗MedPage Today ↗
  2. 13 Nov
    New development

    Doubts emerge over Trump's FDA pick Heidi Overton

    Doubts have emerged among Senate Republicans about Heidi Overton, President Trump's pick to run the FDA, just days before a key vote on her nomination. The FDA has also quietly scuttled the fast-track drug review initiative known as the Commissioner's National Priority Voucher program. The news arrives as the agency faces scrutiny over other health policy decisions and funding cuts.

    MedPage Today ↗
  3. 11 Nov
    New development

    Senate health committee schedules vote on FDA commissioner nominee Overton

    The Senate health committee has scheduled a vote for November 18 on the nomination of Heidi Overton to serve as Food and Drug Administration commissioner. Committee Chair Bill Cassidy remains undecided, and the nomination faces potential opposition from Republicans on the panel. If it passes, the nomination will go to the full Senate, where Republicans are seeking to confirm nominees before Democrats take power in January.

    STAT ↗

Key facts

The Senate health committee scheduled a vote for November 18 on Heidi Overton's FDA commissioner nomination.Reported by STAT
Committee Chair Bill Cassidy remained undecided about Overton's nomination.Reported by STAT
The FDA quietly scuttled the Commissioner's National Priority Voucher program.Reported by MedPage Today
The White House withdrew Heidi Overton's nomination to lead the FDA.Reported by The Hill and STAT
Republicans hold a one-vote majority in the Senate health committee.Reported by The Hill and STAT

What’s still unknown

Whether the White House will nominate another FDA commissioner
How the withdrawal affects the FDA's health policy decisions and funding cuts

All sources

6 articles

In the daily editions

Related developing stories

Follow this story by email

Get one email when there’s a new update, no more than one a day.